Exact Mass: 539.2451978
Exact Mass Matches: 539.2451978
Found 300 metabolites which its exact mass value is equals to given mass value 539.2451978
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
5,9,11-trihydroxyprosta-6E,14Z-dien-1-oate
5,9,11-trihydroxyprosta-6E,14Z-dien-1-oate, also known as Phorbol 12-(2-methylamino)benzoate 13-acetate or CCRIS 7233, is classified as a member of the Phorbol esters. Phorbol esters are tigliane diterpenoids which are esters of phorbol. 5,9,11-trihydroxyprosta-6E,14Z-dien-1-oate is considered to be practically insoluble (in water) and relatively neutral D009676 - Noxae > D002273 - Carcinogens > D010703 - Phorbol Esters
Nintedanib
C31H33N5O4 (539.2532418000001)
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164035 - FGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C155727 - FGFR Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor D000970 - Antineoplastic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
8beta,9alpha-dihydroxy-10-O-methyl-10-epiryanodine
Nintedanib
C31H33N5O4 (539.2532418000001)
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164035 - FGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C155727 - FGFR Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor D000970 - Antineoplastic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Ala Met Arg Tyr
Ala Met Tyr Arg
Ala Arg Met Tyr
Ala Arg Tyr Met
Ala Thr Trp Tyr
Ala Thr Tyr Trp
Ala Trp Thr Tyr
Ala Trp Tyr Thr
Ala Tyr Met Arg
Ala Tyr Arg Met
Ala Tyr Thr Trp
Ala Tyr Trp Thr
Cys Arg Val Tyr
Cys Arg Tyr Val
Cys Val Arg Tyr
Cys Val Tyr Arg
Cys Tyr Arg Val
Cys Tyr Val Arg
Asp Phe Lys Met
Asp Phe Met Lys
Asp Lys Phe Met
Asp Lys Met Phe
Asp Met Phe Lys
Asp Met Lys Phe
Phe Asp Lys Met
Phe Asp Met Lys
Phe Lys Asp Met
Phe Lys Met Asp
Phe Met Asp Lys
Phe Met Lys Asp
Phe Met Arg Ser
Phe Met Ser Arg
Phe Asn Pro Tyr
Phe Asn Tyr Pro
Phe Pro Asn Tyr
Phe Pro Tyr Asn
Phe Arg Met Ser
Phe Arg Ser Met
Phe Ser Met Arg
Phe Ser Arg Met
Phe Ser Thr Trp
Phe Ser Trp Thr
Phe Thr Ser Trp
Phe Thr Trp Ser
Phe Trp Ser Thr
Phe Trp Thr Ser
Phe Tyr Asn Pro
Phe Tyr Pro Asn
His Pro Thr Trp
His Pro Trp Thr
His Gln Gln Gln
His Thr Pro Trp
His Thr Trp Pro
His Trp Pro Thr
His Trp Thr Pro
Ile Met Asn Tyr
Ile Met Tyr Asn
Ile Asn Met Tyr
Ile Asn Tyr Met
Ile Tyr Met Asn
Ile Tyr Asn Met
Lys Asp Phe Met
Lys Asp Met Phe
Lys Phe Asp Met
Lys Phe Met Asp
Lys Met Asp Phe
Lys Met Phe Asp
Leu Met Asn Tyr
Leu Met Tyr Asn
Leu Asn Met Tyr
Leu Asn Tyr Met
Leu Tyr Met Asn
Leu Tyr Asn Met
Met Ala Arg Tyr
Met Ala Tyr Arg
Met Asp Phe Lys
Met Asp Lys Phe
Met Phe Asp Lys
Met Phe Lys Asp
Met Phe Arg Ser
Met Phe Ser Arg
Met Ile Asn Tyr
Met Ile Tyr Asn
Met Lys Asp Phe
Met Lys Phe Asp
Met Leu Asn Tyr
Met Leu Tyr Asn
Met Asn Ile Tyr
Met Asn Leu Tyr
Met Asn Tyr Ile
Met Asn Tyr Leu
Met Gln Val Tyr
Met Gln Tyr Val
Met Arg Ala Tyr
Met Arg Phe Ser
Met Arg Ser Phe
Met Arg Tyr Ala
Met Ser Phe Arg
Met Ser Arg Phe
Met Val Gln Tyr
Met Val Tyr Gln
Met Tyr Ala Arg
Met Tyr Ile Asn
Met Tyr Leu Asn
Met Tyr Asn Ile
Met Tyr Asn Leu
Met Tyr Gln Val
Met Tyr Arg Ala
Met Tyr Val Gln
Asn Phe Pro Tyr
Asn Phe Tyr Pro
Asn Ile Met Tyr
Asn Ile Tyr Met
Asn Leu Met Tyr
Asn Leu Tyr Met
Asn Met Ile Tyr
Asn Met Leu Tyr
Asn Met Tyr Ile
Asn Met Tyr Leu
Asn Pro Phe Tyr
Asn Pro Tyr Phe
Asn Tyr Phe Pro
Asn Tyr Ile Met
Asn Tyr Leu Met
Asn Tyr Met Ile
Asn Tyr Met Leu
Asn Tyr Pro Phe
Pro Phe Asn Tyr
Pro Phe Tyr Asn
Pro His Thr Trp
Pro His Trp Thr
Pro Asn Phe Tyr
Pro Asn Tyr Phe
Pro Thr His Trp
Pro Thr Trp His
Pro Trp His Thr
Pro Trp Thr His
Pro Tyr Phe Asn
Pro Tyr Asn Phe
Gln His Gln Gln
Gln Met Val Tyr
Gln Met Tyr Val
Gln Gln His Gln
Gln Gln Gln His
Gln Val Met Tyr
Gln Val Tyr Met
Gln Tyr Met Val
Gln Tyr Val Met
Arg Ala Met Tyr
Arg Ala Tyr Met
Arg Cys Val Tyr
Arg Cys Tyr Val
Arg Phe Met Ser
Arg Phe Ser Met
Arg Met Ala Tyr
Arg Met Phe Ser
Arg Met Ser Phe
Arg Met Tyr Ala
Arg Ser Phe Met
Arg Ser Met Phe
Arg Val Cys Tyr
Arg Val Tyr Cys
Arg Tyr Ala Met
Arg Tyr Cys Val
Arg Tyr Met Ala
Arg Tyr Val Cys
Ser Phe Met Arg
Ser Phe Arg Met
Ser Phe Thr Trp
Ser Phe Trp Thr
Ser Met Phe Arg
Ser Met Arg Phe
Ser Arg Phe Met
Ser Arg Met Phe
Ser Thr Phe Trp
Ser Thr Trp Phe
Ser Trp Phe Thr
Ser Trp Thr Phe
Thr Ala Trp Tyr
Thr Ala Tyr Trp
Thr Phe Ser Trp
Thr Phe Trp Ser
Thr His Pro Trp
Thr His Trp Pro
Thr Pro His Trp
Thr Pro Trp His
Thr Ser Phe Trp
Thr Ser Trp Phe
Thr Trp Ala Tyr
Thr Trp Phe Ser
Thr Trp His Pro
Thr Trp Pro His
Thr Trp Ser Phe
Thr Trp Tyr Ala
Thr Tyr Ala Trp
Thr Tyr Trp Ala
Val Cys Arg Tyr
Val Cys Tyr Arg
Val Met Gln Tyr
Val Met Tyr Gln
Val Gln Met Tyr
Val Gln Tyr Met
Val Arg Cys Tyr
Val Arg Tyr Cys
Val Tyr Cys Arg
Val Tyr Met Gln
Val Tyr Gln Met
Val Tyr Arg Cys
Trp Ala Thr Tyr
Trp Ala Tyr Thr
Trp Phe Ser Thr
Trp Phe Thr Ser
Trp His Pro Thr
Trp His Thr Pro
Trp Pro His Thr
Trp Pro Thr His
Trp Ser Phe Thr
Trp Ser Thr Phe
Trp Thr Ala Tyr
Trp Thr Phe Ser
Trp Thr His Pro
Trp Thr Pro His
Trp Thr Ser Phe
Trp Thr Tyr Ala
Trp Tyr Ala Thr
Trp Tyr Thr Ala
Tyr Ala Met Arg
Tyr Ala Arg Met
Tyr Ala Thr Trp
Tyr Ala Trp Thr
Tyr Cys Arg Val
Tyr Cys Val Arg
Tyr Phe Asn Pro
Tyr Phe Pro Asn
Tyr Ile Met Asn
Tyr Ile Asn Met
Tyr Leu Met Asn
Tyr Leu Asn Met
Tyr Met Ala Arg
Tyr Met Ile Asn
Tyr Met Leu Asn
Tyr Met Asn Ile
Tyr Met Asn Leu
Tyr Met Gln Val
Tyr Met Arg Ala
Tyr Met Val Gln
Tyr Asn Phe Pro
Tyr Asn Ile Met
Tyr Asn Leu Met
Tyr Asn Met Ile
Tyr Asn Met Leu
Tyr Asn Pro Phe
Tyr Pro Phe Asn
Tyr Pro Asn Phe
Tyr Gln Met Val
Tyr Gln Val Met
Tyr Arg Ala Met
Tyr Arg Cys Val
Tyr Arg Met Ala
Tyr Arg Val Cys
Tyr Thr Ala Trp
Tyr Thr Trp Ala
Tyr Val Cys Arg
Tyr Val Met Gln
Tyr Val Gln Met
Tyr Val Arg Cys
Tyr Trp Ala Thr
Tyr Trp Thr Ala
Amcasertib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor
(3S,6aS,8S,10aS)-3-hydroxy-8-[2-[2-(1-methylimidazol-4-yl)ethylamino]-2-oxoethyl]-N-[4-(trifluoromethyl)phenyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3R,6aR,8R,10aR)-3-hydroxy-8-[2-[2-(1-methyl-4-imidazolyl)ethylamino]-2-oxoethyl]-N-[4-(trifluoromethyl)phenyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3S,6aR,8R,10aR)-3-hydroxy-8-[2-[2-(1-methyl-4-imidazolyl)ethylamino]-2-oxoethyl]-N-[4-(trifluoromethyl)phenyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3S,6aR,8S,10aR)-3-hydroxy-8-[2-[2-(1-methyl-4-imidazolyl)ethylamino]-2-oxoethyl]-N-[4-(trifluoromethyl)phenyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3R,6aR,8S,10aR)-3-hydroxy-8-[2-[2-(1-methyl-4-imidazolyl)ethylamino]-2-oxoethyl]-N-[4-(trifluoromethyl)phenyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3R,6aS,8S,10aS)-3-hydroxy-8-[2-[2-(1-methyl-4-imidazolyl)ethylamino]-2-oxoethyl]-N-[4-(trifluoromethyl)phenyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3S,6aS,8R,10aS)-3-hydroxy-8-[2-[2-(1-methyl-4-imidazolyl)ethylamino]-2-oxoethyl]-N-[4-(trifluoromethyl)phenyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
Sapintoxin d
A phorbol ester consisting of phorbol that is acylated at positions 12 and 13 by 2-(methylamino)benzoyl and acetyl groups respectively. D009676 - Noxae > D002273 - Carcinogens > D010703 - Phorbol Esters
Akt1/Akt2-IN-1
Akt1/Akt2-IN-1 (Compound 17) is an allosteric inhibitor of Akt1 (IC50=3.5 nM) and Akt2 (IC50=42 nM), with potent and balanced activity[1].
MDM2-p53-IN-16
MDM2-p53-IN-16 is a MDM2-p53 complex inhibitor with an IC50 value of 4.3 nM to dissociate human p53/MDM2 complex. MDM2-p53-IN-16 reactivates p53, and induces Glioblastoma Multiforme (GBM) cell apoptosis and cell-cycle arrest. MDM2-p53-IN-16 can be used for the cancer research[1].